QuidelOrtho Corporation (QDEL) SEC Filings & Earnings Calls

High leverage with covenant relief suggests financial stress.

“covenant relief period through Sep 2029 with max leverage 5.5x to 4.25x”

China revenue decline

“China segment revenue $67.8M vs $83.4M (-18.7% YoY)”

High leverage and interest expense

“Interest expense, net $54.7M vs $40.5M; Total borrowings $2,891.1M”

Negative operating cash flow

“Net cash used for operating activities ($143.6M) vs $18.8M”

Litigation risk

“The Company is subject to securities class action and derivative lawsuits related to COVID-19 test sales and SAVANNA assay”

China IVD pricing changes and softer respiratory environment are significant headwinds.

“Demand headwinds in China related to the proposed IVD pricing guidelines and a softer global respiratory environment are continuing to impact our business.” · word for word

Free cash flow guidance withdrawn due to working capital impacts.

“we have decided to withdraw free cash flow guidance as we work through the associated impacts on working capital” · word for word

Transition risk mitigated by planned retirement and overlap period.

“Mr. Busky has agreed to continue to serve in his current role through the Effective Date ... transition and retirement agreement.”

Revenue concentration in respiratory products

“Revenues related to the Company’s respiratory products accounted for 11% and 17% of Total revenues for the three months ended March 29, 2026 and March 30, 2025, respectively.” · word for word

Customer concentration

“For the three months ended March 29, 2026 and March 30, 2025, one customer represented 11% and 13% of Total revenues, respectively.” · word for word

High debt and interest expense

“Interest expense, net $51.1 for the three months ended March 29, 2026 compared to $40.0 for the three months ended March 30, 2025.”

China reimbursement risk

“changes in reimbursement rates for our products, including reimbursement rate reductions proposed by the China National Health Security Administration” · word for word

Litigation risk

“On April 12, 2024, a purported stockholder of the Company filed a putative class action complaint under the federal securities laws against the Company and three of its current and former executives.” · word for word

China NHSA IVD pricing guidelines pose significant uncertainty to Labs revenue

“Pending changes to China NHSA IVD pricing guidelines causing slower distributor sales in China”

Middle East conflict causing business disruption

“Business disruption related to the Middle East conflict” · word for word

Weak respiratory season significantly impacted Point of Care revenue (-34%)

“Point of Care revenue declined 34% primarily due to a significantly weaker respiratory season”

Material weaknesses in internal control over financial reporting

“Ernst & Young's report noted that the Company identified material weaknesses related to (1) revenue, accounts receivable and accrued rebates due to undue reliance on information generated from certain software solutions and design and operating deficiencies related to management review controls, and (2) insufficient controls over the evaluation of all availa” · word for word

Goodwill impairment risk

“Goodwill impairment charge 700.7” · word for word

Contract termination cost

“Contract termination cost 65.0” · word for word

Weaker respiratory season, China NHSA reimbursement cuts, and Middle East conflict delays pose significant revenue risks.

“U.S. Influenza-like Illness visits down ~30% vs Q1 2025; China NHSA reimbursement reductions; EMEA orders delayed by Middle East conflict.” · word for word

Negative free cash flow in Q1 2026, though expected to be positive for full year.

“Free cash flow expected $(65)-$(70)M in Q1 2026.”

Minimal risk; orderly transition with advisory period.

“Ms. Hodges will serve in an advisory role to facilitate a smooth transition.” · word for word

Tariff cost increases

“Currently, as a result of recently effected tariffs, we are incurring incremental costs of parts and materials that we use to produce products, as well as incremental costs to ship finished goods to customers.” · word for word

Respiratory product revenue concentration

“sales of our respiratory products accounted for approximately 15% of our total revenues for the year ended December 28, 2025.” · word for word

China VBP expansion

“the Chinese government has started to expand its volume-based procurement (“VBP”) program to diagnostics at the provincial level, which aims to lower prices in exchange for high volume purchases.” · word for word

PAMA reimbursement cuts

“CMS implemented certain provisions of PAMA, which made substantial changes to the way in which clinical laboratory services are paid under Medicare.” · word for word

Supply chain disruptions

“we have experienced shortages and delays in receiving certain raw materials and other components for our products and have experienced logistics and distribution challenges.” · word for word

CFO departure may create uncertainty in financial leadership

“CFO retirement effective June 30, 2026”

CFO retirement introduces leadership transition risk.

“Joseph M. Busky, Chief Financial Officer, has decided to retire, effective June 30, 2026.” · word for word

GAAP net loss of $131M in Q4 and $1.13B for FY25 due to goodwill impairment and other charges.

“GAAP net loss was $131 million; GAAP net loss was $1.13 billion.” · word for word

Minimal risk; departure is amicable and not related to company operations.

“No dispute or disagreement with the Company, the Board or management.”

COVID-19 revenue decline continues to impact respiratory segment.

“Respiratory revenue of $112 million was down 32% year-over-year, primarily impacted by lower COVID-19 sales, which decreased by 63%.” · word for word

Restructuring execution risk

“The cumulative pre-tax charges to be incurred by the Company to implement the Optimization Plan are expected to be approximately $100 million through 2027.” · word for word

Litigation risk

“A purported stockholder of the Company filed a putative class action complaint under the federal securities laws... The Company disputes the allegations of wrongdoing and intends to defend itself vigorously.” · word for word

High leverage

“Total borrowings were $2,659.0 million as of September 28, 2025, with a maximum Consolidated Leverage Ratio of 4.50 to 1.00.”

Goodwill impairment signals potential overpayment for acquisitions; stock price decline may persist.

“non-cash goodwill impairment charge of $701 million due to a decrease in the estimated fair value related to the decline in the Company’s stock price and market capitalization” · word for word

COVID-19 revenue decline continues, but respiratory segment still volatile.

“Respiratory revenue was $112 million as reported; the decline was primarily driven by a 63% decrease in COVID-19 revenue” · word for word